Take orally at least one hour before or two hours after a meal. Swallow whole with water.

Erlotinib inhibits the intracellular phosphorylation of the tyrosine kinase associated with the epidermal growth factor receptor (EGFR). This inhibition blocks the signal transduction pathways involved in cell proliferation and survival in cancer cells.

• •Known hypersensitivity to Erlotinib or any excipients
• •Co-administration with potent CYP3A4 inhibitors (e.g., ketoconazole) should be avoided or managed with caution.

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

Reported overdose symptoms include severe diarrhea, rash, and liver enzyme elevations. No specific antidote. Management should be supportive.

Pregnancy Category D. May cause fetal harm. Avoid use during pregnancy. Advise women of childbearing potential to use effective contraception. It is not known whether erlotinib is excreted in human milk; due to potential for serious adverse reactions in nursing infants, women should not breastfeed during treatment.